These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 22577239)

  • 1. Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT.
    Rahbar K; Seifarth H; Schäfers M; Stegger L; Hoffmeier A; Spieker T; Tiemann K; Maintz D; Scheld HH; Schober O; Weckesser M
    J Nucl Med; 2012 Jun; 53(6):856-63. PubMed ID: 22577239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
    Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
    Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respiratory-gated imaging in metabolic evaluation of small solitary pulmonary nodules: 18F-FDG PET/CT and correlation with histology.
    Farid K; Poullias X; Alifano M; Regnard JF; Servois V; Caillat-Vigneron N; Petras S
    Nucl Med Commun; 2015 Jul; 36(7):722-7. PubMed ID: 25793929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules.
    Takanami K; Hiraide T; Tsuda M; Nakamura Y; Kaneta T; Takase K; Fukuda H; Takahashi S
    Ann Nucl Med; 2011 Aug; 25(7):501-10. PubMed ID: 21537945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
    Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
    J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
    Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
    J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG-PET/CT for diagnosis of primary ovarian cancer.
    Kitajima K; Suzuki K; Senda M; Kita M; Nakamoto Y; Onishi Y; Maeda T; Yoshikawa T; Ohno Y; Sugimura K
    Nucl Med Commun; 2011 Jul; 32(7):549-53. PubMed ID: 21407140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of MR imaging and FDG-PET/CT in the differential diagnosis of benign and malignant vertebral compression fractures.
    Cho WI; Chang UK
    J Neurosurg Spine; 2011 Feb; 14(2):177-83. PubMed ID: 21214309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of SUV(max) obtained by 18F-FDG PET/CT in patients with a solitary pancreatic lesion: predicting malignant potential and proliferation.
    Hu SL; Yang ZY; Zhou ZR; Yu XJ; Ping B; Zhang YJ
    Nucl Med Commun; 2013 Jun; 34(6):533-9. PubMed ID: 23503000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative analysis of myocardial 18F-fluorodeoxyglucose uptake by PET/CT for detection of cardiac sarcoidosis.
    Yokoyama R; Miyagawa M; Okayama H; Inoue T; Miki H; Ogimoto A; Higaki J; Mochizuki T
    Int J Cardiol; 2015 Sep; 195():180-7. PubMed ID: 26043154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of hexokinase-2 in giant cell tumor of bone is associated with false positive in bone tumor on FDG-PET/CT.
    Hoshi M; Takada J; Oebisu N; Hata K; Ieguchi M; Nakamura H
    Arch Orthop Trauma Surg; 2012 Nov; 132(11):1561-8. PubMed ID: 22825642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
    Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
    J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total lesion glycolysis as the best 18F-FDG PET/CT parameter in differentiating intermediate-high risk adrenal incidentaloma.
    Kim YI; Cheon GJ; Paeng JC; Cho JY; Kang KW; Chung JK; Kim EE; Lee DS
    Nucl Med Commun; 2014 Jun; 35(6):606-12. PubMed ID: 24598843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interobserver variability among measurements of the maximum and mean standardized uptake values on (18)F-FDG PET/CT and measurements of tumor size on diagnostic CT in patients with pulmonary tumors.
    Huang YE; Chen CF; Huang YJ; Konda SD; Appelbaum DE; Pu Y
    Acta Radiol; 2010 Sep; 51(7):782-8. PubMed ID: 20707663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
    Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
    Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.